Bringing ME/CFS Research to More Physicians at AAMP 2026

Earlier this month, the Terra Biological team traveled to Scottsdale, Arizona, to exhibit at the 20th International Conference: Chronic Disease Epidemic – Advanced Applications, held October 2–4.

We spent the weekend connecting with physicians, answering questions about Oxaloacetate CFS, and sharing the latest research on oxaloacetate and fatigue.

Here are three highlights from our time at AAMP.

1. Getting Research Into More Physicians' Hands

One of our biggest goals was introducing more healthcare providers to the published research on oxaloacetate.

We shared clinical findings showing average fatigue reductions of approximately 25–35%, with roughly 40% of participants in one study experiencing even greater improvements.

It's encouraging to have opportunities to bring this research directly to physicians who treat patients with complex chronic conditions.

2. Talking to Doctors about the Medical Food

We also had the opportunity to discuss how Oxaloacetate CFS may fit into their patient care, answer questions about the clinical studies, and introduce physicians to our wholesale program.

With treatment options for ME/CFS still limited, we want more healthcare providers to be familiar with the research and resources available to them.

3. Sharing Research on Long COVID

Long COVID was another important part of our conversations.

We highlighted published findings reporting fatigue reductions of up to 47% over six weeks in Long COVID participants meeting ME/CFS criteria.

As research into these overlapping conditions continues, we're glad to help bring these findings to more clinicians.

Looking Ahead

We left Scottsdale grateful for the conversations and the opportunity to get ME/CFS research in front of more healthcare professionals.

Thank you to everyone who stopped by our booth! We're looking forward to continuing these conversations and connecting with more physicians.

Explore the research: oxaloacetatecfs.com/doctors